Alcon`s directors maintained the full merger, said the offer was “grossly insufficient” and opposed Novartis` “coercive measure.” Alcon, Inc. is the global leader in eye care with revenue of approximately $6.5 billion in 2009. Alcon, which has been dedicated to ophthalmology for 65 years, studies, develops, produces and markets pharmaceuticals, surgical devices and apparatus, contact lens solutions and other visual products that treat diseases, disorders and other eye diseases. Alcon is present in 75 countries and markets products in 180 markets. For more information about Alcon, Inc., please visit the company`s website at www.alcon.com. Alcon Inc. announced on December 15 On December 1, the Board of Directors approved a merger agreement with Novartis AG, under which Novartis will pay an overall underperformance of $168 per share for Alcon shares it does not currently own. Pursuant to the terms of the transaction, the underperformance of the merger will consist of a combination of Novartis shares and, where applicable, a cash amount resulting in a total value of $US 168 per share. The exact exchange rate ratio and the quota value are calculated on the basis of the formulas defined in the merger contract. Caution with forward-looking statements. This press release may contain forward-looking statements within the meaning of the U.S.

Private Securities Reform Act of 1995. All forward-looking statements reflect the views of our management at the time of this press release on future events and are based on assumptions and are subject to risks and uncertainties. In the face of these uncertainties, do not place too much reliance on these forward-looking statements. It cannot be guaranteed that Novartis or Alcon will achieve any future financial results or future growth rates, or that Novartis or Alcon will be able to realize synergies, strategic benefits or potential opportunities as a result of the execution of the proposed merger. . . .